Patents by Inventor Louise Sargent

Louise Sargent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20230365549
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: April 3, 2023
    Publication date: November 16, 2023
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
    Patent number: 11643408
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 9, 2023
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20210046076
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: September 1, 2020
    Publication date: February 18, 2021
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
    Patent number: 10793560
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 6, 2020
    Assignee: RedX Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20180319788
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 8, 2018
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway
    Patent number: 10047079
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: August 14, 2018
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20170275276
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: October 8, 2015
    Publication date: September 28, 2017
    Applicant: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue